{"transactions":[{"id":692040,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2026-08-10T20:30:11.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":false,"shares":18181818,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Redeemable Convertible Preferred Stock (\"Series C Preferred Stock\") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Redeemable Convertible Preferred Stock (\"Series C Preferred Stock\") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Redeemable Convertible Preferred Stock (\"Series C Preferred Stock\") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"derivative":{"underlying":"Common Stock","underlying_shares":1957138},"source":{"system":"sec-edgar","filing":"0001193125-26-342487","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000119312526342487/ownership.xml","form_type":"4"}},{"id":692039,"issuer":{"id":4984,"kind":"organization","name":"Attovia Therapeutics, Inc.","symbol":"ATTO"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-10T20:30:11.000Z","date":"2026-08-06","kind":"exercise","planned":false,"acquired":true,"shares":1957138,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Redeemable Convertible Preferred Stock (\"Series C Preferred Stock\") automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at the applicable conversion ratio of 9.29-for-one. The Series C Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":1957138,"source":{"system":"sec-edgar","filing":"0001193125-26-342487","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000119312526342487/ownership.xml","form_type":"4"}},{"id":699056,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-08-03T23:28:30.000Z","date":"2026-07-30","kind":"purchase","planned":false,"acquired":true,"shares":286205,"price":34.9399,"value":9999974.0795,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":664649,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":286205},"source":{"system":"sec-edgar","filing":"0001193125-26-331058","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000119312526331058/ownership.xml","form_type":"4"}},{"id":910518,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2026-02-11T16:30:23.000Z","date":"2026-02-10","kind":"other","planned":false,"acquired":false,"shares":15726349,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\").  Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Persons were tendered in exchange for the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") by and among the Issuer, SANOFI, a French societe anonyme (\"Parent\"), and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\").  Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the \"Common Stock\"), for $15.50 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On February 10, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Persons were tendered in exchange for the Offer Price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-046675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000119312526046675/ownership.xml","form_type":"4"}},{"id":912469,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67079,"kind":"organization","name":"Deep Track Special Opportunities Fund, LP","position":2,"cik":"0002077950","reported_name":"Deep Track Special Opportunities Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":3,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":4,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-02-10T16:30:04.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":93925,"price":21.1699,"value":1988382.8575,"ownership":{"direct":false,"nature":"By Deep Track Special Opportunities Fund, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":93925,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":93925},"source":{"system":"sec-edgar","filing":"0001193125-26-044776","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2077950/000119312526044776/ownership.xml","form_type":"4"}},{"id":912468,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":67079,"kind":"organization","name":"Deep Track Special Opportunities Fund, LP","position":2,"cik":"0002077950","reported_name":"Deep Track Special Opportunities Fund, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":3,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":4,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-02-10T16:30:04.000Z","date":"2026-02-06","kind":"purchase","planned":false,"acquired":true,"shares":378444,"price":21.1699,"value":8011621.6356,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Pre-Funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Pre-Funded Warrants do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Under the terms of the Pre-Funded Warrants held by the Reporting Persons, the Issuer may not effect the exercise of any such Pre-Funded Warrant, and a holder will not be entitled to exercise any portion of any such Pre-Funded Warrant (i) if immediately prior to the exercise, the Reporting Persons (together with its affiliates), beneficially owns an aggregate number of shares of Issuer Common Stock greater than 9.99%, as applicable (the \"Maximum Percentage\"), of the total number of issued and outstanding shares of Common Stock of the Issuer without taking into account any shares underlying such Pre-Funded Warrants, or (ii) to the extent that immediately following the exercise, the holder (together with its affiliates) would beneficially own in excess of the Maximum Percentage of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of such shares of Common Stock."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP, and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":378444,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":378444},"source":{"system":"sec-edgar","filing":"0001193125-26-044776","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2077950/000119312526044776/ownership.xml","form_type":"4"}},{"id":1039544,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":false,"shares":16666667,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":686138},"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039543,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":666666,"price":15,"value":9999990.0,"ownership":{"direct":false,"nature":"By Deep Track Special Opportunities Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held by Deep Track Special Opportunities Fund, LP.   Deep Track Capital, LP is the investment manager of Deep Track Special Opportunities Fund LP. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":666666,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039542,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"purchase","planned":false,"acquired":true,"shares":2000000,"price":15,"value":30000000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":2686138,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1039541,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-16T22:09:13.000Z","date":"2025-09-12","kind":"exercise","planned":false,"acquired":true,"shares":686138,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":686138,"source":{"system":"sec-edgar","filing":"0002015536-25-000007","document":"form4-09162025_100907.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2015536/000201553625000007/form4-09162025_100907.xml","form_type":"4"}},{"id":1058596,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2025-08-22T20:49:18.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":970143,"price":10.59,"value":10273814.37,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"In addition to Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands exempted company (\"DTBMF\"), this Form 4 is being filed jointly by Deep Track Capital, LP, a Delaware limited partnership (\"Deep Track LP\"), and David Kroin, a citizen of the United States of America and the managing member of the general partner of Deep Track LP (together with DTBMF and Deep Track LP, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the \"Subject Securities\"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities."}],"balance_after":15726349,"source":{"system":"sec-edgar","filing":"0000950170-25-111070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017025111070/ownership.xml","form_type":"4"}},{"id":1058595,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":1,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":2,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2025-08-22T20:49:18.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":1094994,"price":11.03,"value":12077783.82,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"In addition to Deep Track Biotechnology Master Fund, Ltd., a Cayman Islands exempted company (\"DTBMF\"), this Form 4 is being filed jointly by Deep Track Capital, LP, a Delaware limited partnership (\"Deep Track LP\"), and David Kroin, a citizen of the United States of America and the managing member of the general partner of Deep Track LP (together with DTBMF and Deep Track LP, the \"Reporting Persons\"). Each of the Reporting Persons may be deemed to have a pecuniary interest in the securities reported on this Form 4 (the \"Subject Securities\"). Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Each of the Reporting Persons may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Subject Securities."}],"balance_after":16696492,"source":{"system":"sec-edgar","filing":"0000950170-25-111070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017025111070/ownership.xml","form_type":"4"}},{"id":1519687,"issuer":{"id":4364,"kind":"organization","name":"NEKTAR THERAPEUTICS","symbol":"NKTR"},"owners":[{"id":25080,"kind":"organization","name":"Deep Track Capital, LP","position":1,"cik":"0001856083","reported_name":"Deep Track Capital, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25079,"kind":"organization","name":"Deep Track Biotechnology Master Fund, Ltd.","position":2,"cik":"0002015536","reported_name":"Deep Track Biotechnology Master Fund, Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25081,"kind":"person","name":"KROIN DAVID","position":3,"cik":"0001397513","reported_name":"KROIN DAVID","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-05-13T20:36:00.000Z","date":"2024-05-10","kind":"sale","planned":false,"acquired":false,"shares":56000,"price":1.7791,"value":99629.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.745 to $1.81, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP. is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, L.P. and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests."}],"balance_after":18344000,"source":{"system":"sec-edgar","filing":"0000950170-24-058720","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/906709/000095017024058720/ownership.xml","form_type":"4"}}]}